Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction

Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction

Patients with coronary artery disease remain at increased risk of recurrent life-threatening cardiovascular events even after adequate guideline-based treatment of conventional risk factors, including blood lipid levels. Inflammation is a critical pathway in the pathogenesis of atherosclerosis and i...

Full description

Bibliographic Details
Main Authors: Eva Prescott, John Pernow, Antti Saraste, Axel Åkerblom, Oskar Angerås, David Erlinge, Erik L. Grove, Marja Hedman, Lisette O. Jensen, Sara Svedlund, Magnus Kjaer, Maria Lagerström-Fermér, Li-Ming Gan
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:Contemporary Clinical Trials Communications
Subjects:
5-Lipoxygenase activating protein
Coronary flow reserve
Coronary flow velocity reserve
Leukotrienes
Myocardial infarction
Echocardiography
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865420301137

Internet

http://www.sciencedirect.com/science/article/pii/S2451865420301137

Similar Items